Complete sentinel dosing and initiate expansion dosing for BEAM-101
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2024
- Due
- 30 Jun 2024
- Delivered
- by 30 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Complete sentinel dosing and initiate expansion dosing in first half of 2024”
What we found
Evidence strength A What the grades mean
The company confirmed in August 2024 that the three sentinel cohort patients were dosed and achieved engraftment in May 2024, and that expansion phase dosing had subsequently commenced.
-
A Beam Therapeutics Inc. 10-Q filed 2024-08-06
“In May 2024, we announced that the three patients in the sentinel cohort of the BEACON trial have each been dosed and successfully achieved engraftment.” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 10-Q filed 2024-08-06
“Following engraftment of the third patient, we have dosed three patients in the expansion phase of the trial.” ✓ confirmed on the page
Market reaction: the shares moved -5.3% against the S&P 500 over the three sessions around the disclosure (5 Aug 2024 to 8 Aug 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- BEAM-101 SCD dosing
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-BEAM-003258 · Corrections policy